首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126329

感染疾病診斷市場：策略性洞察與預測（2026-2035 年）

Infectious Disease Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月03日 | 出版商:

Knowledge Sourcing Intelligence | 英文 172 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計感染疾病診斷市場規模將從 2026 年的 261 億美元成長到 2035 年的 469 億美元，複合年成長率為 6.7%。

感染疾病診斷市場正經歷一場重大變革，其驅動力在於快速分子檢測、分散式診斷和整合檢查室生態系統的模式轉移。這一市場演變的特點是，人們日益認知到，早期識別病原體並進行抗藥性分析對於合理使用抗生素、控制感染和進行公共衛生監測至關重要。多重分子診斷、次世代定序、人工智慧和檢查室自動化技術的融合，使得傳染病檢查更加快速、全面且便利。醫療系統正在優先考慮擴充性的診斷平台，以支援常規臨床檢測和應對突發疫情。日益嚴重的抗生素抗藥性問題也改變了對診斷的需求，因為臨床醫生需要在選擇標靶治療之前更早識別病原體並進行抗藥性分析。隨著各國政府將診斷基礎建設視為因應疫情的重要部分，國家層級的疫情防範工作也持續影響採購重點。隨著感染疾病診斷逐漸成為現代醫療保健服務和公共衛生基礎設施的重要組成部分，市場對特定症候群檢測組、即時分子診斷、基因組監測網路和數位報告系統進行了大量投資。

市場促進因素

抗生素抗藥性的日益嚴重是感染疾病診斷市場的主要驅動力。抗菌藥物抗藥性會對臨床治療帶來不確定性，因為經驗性治療往往會延誤最佳治療方案的啟動，並增加不合理使用抗生素的情況。醫療機構擴大採用分子診斷技術，以便在患者早期管理階段同時識別病原體和抗藥性相關的遺傳標記。雖然傳統的微生物學檢測仍能提供明確的診斷結果，但其較長的檢測週期限制了治療方案的即時最佳化。診斷設備製造商正在擴展其快速PCR檢測板、自動化微生物系統和抗藥性檢測方法的產品線，以支援合理使用抗生素的方案，從而推動感染疾病診斷的持續成長。基因組監測的擴展，尤其是透過採用次世代定序，進一步加速了市場成長。病原體監測依賴基因組特徵分析，因為新出現的變異株會影響疾病傳播、疫苗有效性和治療方案的選擇。國家監測計畫正在擴展參考檢查室的定序能力，以加強疫情監測和公共衛生緊急準備。在檢查室基礎設施中，除了定序技術之外，生物資訊學的整合對於管理大規模基因組資料集也日益重要。診斷設備製造商正積極回應這項需求，開發自動化定序工作流程和標準化分析軟體，以簡化常規部署。分散式檢查正在加速即時診斷技術在醫療機構的應用。早期診斷在醫療服務中變得日益重要，因為檢測延誤會導致疾病傳播和住院時間延長。即時分子診斷正在擴展到急診、門診、藥房和社區醫療機構，透過快速臨床決策改善病患管理。即使分散式部署不斷發展，醫療服務提供者仍需要檢查室層級的分析效能。製造商正在開發緊湊型自動化系統，在保持診斷準確性的同時，最大限度地降低操作複雜性。檢查室自動化正在提高營運效率並實現工作流程標準化。臨床檢查室面臨人手不足和營運成本上升的壓力，同時也要應對不斷成長的檢測量。自動化減少了人工檢體處理，提高了工作流程的一致性，並支援每個診斷檢查室的標準化品管。高通量分子診斷平台擴大將樣品製備、擴增、檢測和報告整合到統一的工作流程中。

市場限制因素

儘管臨床需求不斷成長，但先進分子診斷設備所需的高額初始投資限制了其在小規模醫療機構中的應用。設備部署的高前期成本是資源匱乏環境下的一大障礙。不同醫療系統報銷標準的差異降低了檢查室採用新型、高度複雜的分子診斷技術的經濟獎勵。不一致的保險覆蓋政策限制了患者的就醫途徑，並為診斷服務提供者帶來不確定性。多種分子檢測的監管驗證要求增加了研發時間、臨床證據產生成本和商業化成本。嚴格的核准流程對小規模診斷公司構成挑戰。缺乏專業的檢查室人員和分子診斷技術阻礙了先進平台的有效利用，並限制了其在許多醫療機構中的擴充性。

依產品
- 儀器/分析儀
- 試劑和試劑盒
- 軟體和服務
透過技術
- 聚合酵素鏈鎖反應（PCR）
- 恒溫核酸增幅法
- 次世代定序（NGS）
- 免疫測量
- 臨床微生物學
- 其他分子診斷技術
按測試類型
- 檢查室測試
- 即時檢測
依疾病類型
- 病毒感染疾病
  - COVID-19
  - 流感
  - 愛滋病毒/愛滋病
  - 肝炎
  - 人類乳突病毒（HPV）
  - 其他
- 細菌感染疾病
  - 結核病（TB）
  - 院內感染（HAI）
  - 抗藥性金黃色葡萄球菌（MRSA）
  - 性行為感染感染（細菌性行為感染）
  - 其他
- 黴菌感染疾病
- 寄生蟲感染疾病
依樣本類型
- 血
- 血清
- 尿
- 航班
- 組織切片檢查
- 其他檢體類型
最終用戶
- 醫院和診所
- 診斷檢查室
- 學術研究機構
- 其他最終用戶

第10章：全球感染疾病診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球感染疾病診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
墨西哥
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Danaher Corporation
Illumina Inc.
DiaSorin SpA
bioMerieux SA
QIAGEN NV
Becton, Dickinson and Company
Hologic, Inc.
OraSure Technologies Inc.

第14章全球感染疾病診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009042

The Infectious Disease Diagnostics Market is expected to grow at a CAGR of 6.7% from a market value of USD 26.1 billion in 2026 to USD 46.9 billion in 2035.

The infectious disease diagnostics market is undergoing significant transformation driven by the paradigm shift toward rapid molecular testing, decentralized diagnostics, and integrated laboratory ecosystems. The market's evolution is characterized by the growing recognition that early pathogen identification with resistance profiling is essential for antimicrobial stewardship, infection control, and public health surveillance. The convergence of multiplex molecular diagnostics, next-generation sequencing, artificial intelligence, and laboratory automation is enabling faster, more comprehensive, and increasingly accessible infectious disease testing. Healthcare systems are prioritizing scalable diagnostic platforms capable of supporting both routine clinical testing and emergency outbreak response. The increasing burden of antimicrobial resistance is transforming diagnostic demand because clinicians require earlier organism identification together with resistance profiling before selecting targeted therapies. National preparedness initiatives continue to influence procurement priorities because governments recognize diagnostic infrastructure as an essential component of pandemic readiness. The market is witnessing significant investment in syndromic testing panels, point-of-care molecular diagnostics, genomic surveillance networks, and digital reporting systems, positioning infectious disease diagnostics as a critical component of modern healthcare delivery and public health infrastructure.

Market Drivers

Increasing antimicrobial resistance represents the primary driver for the infectious disease diagnostics market. Antimicrobial resistance creates clinical uncertainty because empirical treatment frequently delays optimal therapy while increasing inappropriate antibiotic exposure. Healthcare providers are increasingly adopting molecular diagnostics that identify pathogens together with resistance-associated genetic markers during early patient management. Conventional microbiology continues to provide definitive confirmation, yet its longer turnaround time limits immediate treatment optimization. Diagnostic manufacturers are expanding rapid PCR panels, automated microbiology systems, and resistance detection assays that support antimicrobial stewardship programs, resulting in sustained growth in infectious disease diagnostic utilization. Expanding genomic surveillance is further accelerating market growth through adoption of next-generation sequencing. Pathogen surveillance depends upon genomic characterization because emerging variants influence disease transmission, vaccine effectiveness, and therapeutic selection. National surveillance programs are expanding sequencing capacity across reference laboratories to strengthen outbreak monitoring and public health preparedness. Laboratory infrastructure increasingly requires bioinformatics integration alongside sequencing technologies to manage larger genomic datasets. Diagnostic companies are responding by developing automated sequencing workflows and standardized analysis software that simplify routine implementation. Decentralized testing is accelerating point-of-care diagnostic adoption across healthcare settings. Healthcare delivery increasingly emphasizes earlier diagnosis because delayed testing contributes to disease transmission and prolonged hospitalization. Point-of-care molecular diagnostics are expanding into emergency departments, outpatient clinics, pharmacies, and community healthcare settings where rapid clinical decisions improve patient management. Healthcare providers continue requiring laboratory-quality analytical performance despite decentralized deployment. Manufacturers are developing compact automated systems that minimize operator complexity while maintaining diagnostic accuracy. Laboratory automation is improving operational efficiency and workflow standardization. Clinical laboratories process increasing testing volumes while facing workforce shortages and operational cost pressures. Automation is reducing manual sample handling, improving workflow consistency, and supporting standardized quality management across diagnostic laboratories. High-throughput molecular platforms increasingly integrate sample preparation, amplification, detection, and reporting within unified workflows.

Market Restraints

High capital investment requirements for advanced molecular analyzers limit adoption among smaller healthcare facilities despite increasing clinical demand. The substantial upfront costs for instrumentation create barriers for resource-constrained settings. Reimbursement variability across healthcare systems reduces financial incentives for laboratories to implement newer high-complexity molecular diagnostic technologies. Inconsistent coverage policies limit patient access and create uncertainty for diagnostic providers. Regulatory validation requirements for multiplex molecular assays increase development timelines, clinical evidence generation, and commercialization costs. The rigorous approval processes create challenges for smaller diagnostic companies. Shortages of specialized laboratory professionals and molecular diagnostics expertise constrain efficient utilization of advanced platforms, limiting scalability in many healthcare settings.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of multiplex molecular diagnostics and integrated testing workflows. PCR remains the reference molecular technology because it provides high analytical sensitivity, specificity, and relatively rapid turnaround across a broad spectrum of pathogens. Clinical laboratories are expanding PCR utilization beyond single-pathogen detection toward multiplex respiratory, gastrointestinal, bloodstream, and sexually transmitted infection panels that improve diagnostic efficiency. Next-generation sequencing is gaining adoption for genomic surveillance, outbreak investigation, and antimicrobial resistance monitoring. Immunoassays continue supporting serological testing and rapid antigen detection. Clinical microbiology provides culture confirmation and susceptibility testing, yet longer processing times increase dependence on rapid molecular methods for initial clinical decisions. The segment analysis reveals that reagents and kits represent the largest recurring revenue component because every diagnostic workflow depends on consumables regardless of the installed instrument base. Healthcare providers are increasing testing frequency for respiratory infections, bloodstream infections, healthcare-associated infections, and sexually transmitted diseases, creating sustained demand for assay-specific consumables. Viral infections account for a substantial proportion of diagnostic demand because early pathogen identification directly influences antiviral therapy, infection control, and public health surveillance. Bacterial infections, including tuberculosis, hospital-acquired infections, and sexually transmitted bacterial infections, generate significant demand for rapid resistance detection. Fungal and parasitic infections represent important niche segments. Hospitals and clinics represent key end-user segments, with diagnostic laboratories playing a central role in specialized testing. Point-of-care testing is expanding across decentralized healthcare settings. The integration of AI is becoming increasingly important because diagnostic platforms generate complex molecular and genomic datasets requiring efficient interpretation. AI is assisting laboratories by improving workflow prioritization, quality assurance, and result interpretation across high-volume testing environments.

Competitive and Strategic Outlook

The competitive landscape features established molecular diagnostics and life science companies alongside specialized infectious disease and point-of-care providers. F. Hoffmann-La Roche is a global leader in molecular diagnostics with the cobas portfolio, combining high-throughput automation with extensive infectious disease assay coverage and a strategy focused on integrated laboratory ecosystems and digital connectivity. Abbott offers infectious disease diagnostics across molecular, immunoassay, and rapid testing platforms through its Alinity and ID NOW portfolios, emphasizing decentralized testing and workflow automation. Danaher, through Cepheid and Beckman Coulter, provides rapid PCR, microbiology, and laboratory automation solutions, continuing to expand syndromic molecular diagnostics and antimicrobial resistance testing. Illumina is a leading provider of NGS platforms supporting infectious disease surveillance and pathogen genomics, with a strategy centered on scalable sequencing workflows and bioinformatics integration. DiaSorin develops molecular and immunodiagnostic solutions through its LIAISON platforms, continuing to expand assay menus and laboratory automation capabilities. bioMerieux specializes in clinical microbiology, syndromic molecular diagnostics, and antimicrobial susceptibility testing, supporting antimicrobial stewardship through rapid pathogen identification. QIAGEN provides sample preparation technologies, PCR assays, and syndromic testing through the QIAstat-Dx platform. BD offers automated microbiology systems, molecular diagnostics, and specimen collection solutions. Hologic delivers high-throughput molecular diagnostics through its Panther platform, particularly in sexually transmitted and viral infections. Companies are pursuing product portfolio expansion through innovation in multiplex syndromic panels, rapid point-of-care molecular tests, and AI-enabled interpretation software. Strategic collaborations between diagnostic manufacturers, healthcare providers, and public health agencies are increasing, driven by the need for antimicrobial stewardship and surveillance. Recent key developments include Seegene launching the industry's first Global Million Clinical Study evaluating 1 million real patient test records to validate a syndromic PCR testing strategy. Karius collaborated with Mayo Clinic Laboratories to make metagenomic infectious disease diagnostic tests available through streamlined sample submission. Bruker launched MyGenius PRO, a fully automated PCR-based molecular diagnostics system delivering up to 144 results in 8 hours with high-throughput walkaway automation. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The infectious disease diagnostics market is positioned for sustained growth driven by the convergence of antimicrobial resistance, genomic surveillance, decentralized testing, and laboratory automation. The transition from standalone laboratory testing toward integrated diagnostic ecosystems represents a fundamental shift in infectious disease management. While challenges related to high capital costs, reimbursement variability, and regulatory complexity persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with infectious disease diagnostics evolving into a critical component of modern healthcare delivery, supporting rapid pathogen identification, antimicrobial stewardship, outbreak preparedness, and public health surveillance across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Infectious Disease Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Infectious Disease Diagnostics Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Infectious Disease Burden and Unmet Diagnostic Needs
3.8 Disease Prevalence Analysis
3.9 Diagnosed Patient Population Analysis
3.10 Testing Volume Analysis
3.11 Diagnostic Testing Pathway Analysis

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Diagnostic Technologies
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Diagnostic Pipeline Analysis
6.5 Artificial Intelligence Integration in Infectious Disease Diagnostics
6.6 Digital Health and Connected Diagnostics

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Infectious Disease Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Testing Methodology
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by End User

9. Global Infectious Disease Diagnostics Market Segment Analysis (2021-2035)

9.1 By Product
- 9.1.1 Instruments & Analyzers
- 9.1.2 Reagents & Kits
- 9.1.3 Software & Services
9.2 By Technology
- 9.2.1 Polymerase Chain Reaction (PCR)
- 9.2.2 Isothermal Nucleic Acid Amplification
- 9.2.3 Next-Generation Sequencing (NGS)
- 9.2.4 Immunoassays
- 9.2.5 Clinical Microbiology
- 9.2.6 Other Molecular Diagnostic Technologies
9.3 By Test Type
- 9.3.1 Laboratory-based Testing
- 9.3.2 Point-of-Care Testing
9.4 By Disease Type
- 9.4.1 Viral Infections
  - 9.4.1.1 COVID-19
  - 9.4.1.2 Influenza
  - 9.4.1.3 HIV/AIDS
  - 9.4.1.4 Hepatitis
  - 9.4.1.5 Human Papillomavirus (HPV)
  - 9.4.1.6 Others
- 9.4.2 Bacterial Infections
  - 9.4.2.1 Tuberculosis (TB)
  - 9.4.2.2 Hospital-Acquired Infections (HAIs)
  - 9.4.2.3 Methicillin-resistant Staphylococcus aureus (MRSA)
  - 9.4.2.4 Sexually Transmitted Bacterial Infections
  - 9.4.2.5 Others
- 9.4.3 Fungal Infections
- 9.4.4 Parasitic Infections
9.5 By Sample Type
- 9.5.1 Blood
- 9.5.2 Serum
- 9.5.3 Urine
- 9.5.4 Stool
- 9.5.5 Tissue Biopsy
- 9.5.6 Other Sample Types
9.6 By End User
- 9.6.1 Hospitals & Clinics
- 9.6.2 Diagnostic Laboratories
- 9.6.3 Academic & Research Institutes
- 9.6.4 Other End Users

10. Global Infectious Disease Diagnostics Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Infectious Disease Diagnostics Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia
11.16 South Africa

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Abbott Laboratories
13.3 Danaher Corporation
13.4 Illumina Inc.
13.5 DiaSorin S.p.A.
13.6 bioMerieux SA
13.7 QIAGEN N.V.
13.8 Becton, Dickinson and Company
13.9 Hologic, Inc.
13.10 OraSure Technologies Inc.